YHYu-Sung Hsu

Yu-Sung Hsu

*This is an algorithmically generated author record based on publicly available information.

Yu-Sung Hsu has a total of 41 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Figure 7 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 7 | a, Overlay of predicted mut031 α chain variable region and resolved FMC63 variable chain structure. Modeling performed using AlphaFold2. b, Memory lineages of human T cells engineered to express miTCR1 WT or mut035 at the conclusion of manufacturing cultures. c-d, Proportion of human T cells that were early lineage (naïve or central memory) c, throughout 6 day stimulation manufacturing cultures or d, one day after clearance of Nalm6. e, Expansion of human T cells expressing miTCR1 WT, mut035 or 19/BBζ CAR from two donors. b-d, data from one donor.

  • Open Access

    Supplementary Figure 2 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 2 | a-d, Expression of a, TCR constant chains and mCherry transduction marker, b, FMC63 and mCherry transduction marker, c, FMC63 and TCR constant chains and d, CD3ε and TCR constant chains in primary human T cells engineered with CARs or miTCRs. e, Comparison of surface FMC63 expression in miTCR1 and miTCR2 engineered T cells in n=6 independent donors. f, Median fluorescence intensity (MFI) of APC on T cells that bound soluble CD19-APC conjugate. a-d, Representative of five independent donors. Analysis using Student’s t-test or two-way ANOVA.

  • Open Access

    Supplementary Figure 5 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 5 | a-b, Expression of TCR constant chains on the surface of a, Jurkat and b, human T cells transduced with miTCR variants. c-d, Comparison of surface TCR expression in miTCR1 and miTCR2 variant engineered c, Jurkats and d, human T cells. e, Change in surface expression of TCR constant chains based on presence or absence of PD insertion in the miTCRα chain. f, Expression of NFAT and g, NFκB in reporter Jurkat cells expressing 1G4 or miTCR variants in response to Nalm6. h, Expansion of human T cells expressing miTCR1 and miTCR2 variants upon exposure to Nalm6. d, cumulative data from three independent donors. b,e, representative data from three independent donors. Screening studies in h performed using two independent donors. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by Student’s t-test (c-e).

  • Open Access

    Supplementary Figure 3 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 3 | a, Predicted structures of miTCR1 and miTCR2 α and β chains overlaid on resolved structures of TCR α and β chains. b, Overlay of five highest-ranking predictions for miTCR1 and miTCR2 variable-constant chain interface. c, Resolved native TCR α chain V-C interface structure and predicted V-C interface structures of miTCR2 WT and modified α chains. d, Resolved native TCR β chain V-C interface structure and predicted V-C interface structures of miTCR1 WT, miTCR2 WT and modified β chains.

  • Open Access

    Supplementary Figure 6 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 6 | a-b, Cytotoxicity of a, miTCR1 and b, miTCR2 variants against Nalm6. c-d, Long-term flow cytometry-based cytotoxicity of lead c, miTCR1 and d, miTCR2 variants. e, Quantification of cytokines in supernatants 24h after co-culture of engineered T cells with Nalm6. f, Expression of TCRC chains in αCD22 miTCR1, CD22 miTCR2 and CD19 miTCR1 engineered Jurkat cells. g, Induction of reporter NFAT-GFP upon exposure to CD19+CD22+ Nalm6 in Jurkat cells. Screening studies in a-b performed using two independent donors; c-d, representative data from three independent donors; e, data from one donor. ****P < 0.0001 by two-way ANOVA (c-d).

  • Open Access

    Supplementary Figure 4 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 4 | Names and amino acid changes of miTCR variant panel. PD insertions are highlighted in blue.

  • Open Access

    Supplementary Figure 1 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 1 | a-b, Expression of NFAT and NFκB in reporter Jurkat cells expressing CARs or miTCRs in response to a, CD19+ Nalm6 or CD19- Molm14. b, Representative flow cytometry plot of TCR constant chain expression after dual TRAC and TRBC disruption. c, Summary data of TCR surface expression after dual TRAC and TRBC disruption in n=8 individual donors. Analysis using two-sided Student’s t-test.

  • Open Access

    Supplementary Figure 8 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 8 | a, Cytotoxicity, as measured by fold change in Nalm6 growth during co-culture, and b, expansion of human T cells expressing transgenic TCR 1G4, 19/BBζ or 19/28ζ CAR against Nalm6WT or Nalm6triple. c-d, Endogenous expression of 41BBL, CD80 and CD86 in c, Raji and d, K562 cell lines. e, Growth rate of engineered Nalm6 cell lines. f-g, Cytotoxicity of 19/BBζ CAR and mut035 T cells over time during f, acute stimulation and g, re-stimulation. 19/BBζ CAR were initially co-cultured with Nalm6WT and re-stimulated with Nalm6WT; mut035 T cells were initially co-cultured with Nalm641BBL and re-stimulated with Nalm6WT. h, Percent of cells expressing either 19/BBζ CAR or mut035 miTCR on day 0 or after five days of chronic stimulation with various Nalm6 cell lines. i, Expansion of 19/BBζ CAR or mut035 miTCR T cells over the course of chronic stimulation with various Nalm6 cell lines. a-b and f-g Representative data from three independent donors; i, Representative of five independent donors. Statistical significance determined using two-way ANOVA.

  • Open Access

    Data from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Chimeric antigen receptor (CAR)–based therapies have pioneered synthetic cellular immunity but remain limited in their long-term efficacy. Emerging data suggest that dysregulated CAR-driven T-cell activation causes T-cell dysfunction and therapeutic failure. To re-engage the precision of the endogenous T-cell response, we designed MHC-independent T-cell receptors (miTCR) by linking antibody variable domains to T-cell receptor constant chains. Using predictive modeling, we observed that this standard “cut and paste” approach to synthetic protein design resulted in myriad biochemical conflicts at the hybrid variable–constant domain interface. Through iterative modeling and sequence modifications, we developed structure-enhanced miTCRs which significantly improved receptor-driven T-cell function across multiple tumor models. We found that 41BB costimulation specifically prolonged miTCR T-cell persistence and enabled improved leukemic control in vivo compared with classic CAR T cells. Collectively, we have identified core features of hybrid receptor structure responsible for regulating function.Significance:Improving the durability of engineered T-cell immunotherapies is critical to enhancing efficacy. We used a structure-informed design to evolve improved miTCR function across several models. This work underscores the central role of synthetic receptor structure in T-cell function and provides a framework for improved receptor engineering.

  • Open Access

    Supplementary Figure 1 from Rational Protein Engineering to Enhance MHC-Independent T-cell Receptors

    by Ju-Fang Chang, Jack H. Landmann, Tien-Ching Chang, Mehmet Emrah Selli, Yangdon Tenzin, John M. Warrington, Julie Ritchey, Yu-Sung Hsu, Michael Slade, Deepesh Kumar Gupta, et al.

    Supplementary Figure 1 | a-b, Expression of NFAT and NFκB in reporter Jurkat cells expressing CARs or miTCRs in response to a, CD19+ Nalm6 or CD19- Molm14. b, Representative flow cytometry plot of TCR constant chain expression after dual TRAC and TRBC disruption. c, Summary data of TCR surface expression after dual TRAC and TRBC disruption in n=8 individual donors. Analysis using two-sided Student’s t-test.